Pipeline

We are developing therapeutics designed to modulate the immune system, to overcome cancer immune tolerance and escape. We are also developing therapeutics designed to treat autoimmune diseases.

KY1005, KY1044 and KY1043 are designed to balance the activation and suppression of the immune system to treat disease.

Our pipeline

We are building a rich pipeline of assets in four main therapeutic spaces: immune diseases, immuno-oncology, haematology and infectious diseases. Our most advanced assets entered development in 2017, and our first proof-of-concept clinical data is expected in 2020.

Read about our progress in our Posters and publications page

Quick links

About

Since our founding in 2010, Kymab has raised $220 million in equity financing from leading investors to enable us to develop our unique antibody platforms and create a portfolio of therapeutic antibody assets.